Sign In
Buy IBB
$167.50
+3.23 (+1.97%)
At Close: Jun 03, 2026
Healthcare Dashboard For August
11:59am, Tuesday, 18'th Aug 2020
A dashboard with metrics of value, quality and momentum by industries. Value and quality scores relative to historical averages.
Novavax's stock surges after supply deal with South Korea's SK Group for COVID-19 vaccine candidate
12:45pm, Thursday, 13'th Aug 2020
Shares of Novavax Inc. rallied 2.8% in premarket trading Thursday, after the biotechnology company said it has entered into a development and supply agreement with South Korea-based SK Group subsidia
Seres Therapeutics stock rockets nearly fourfold after positive Phase 3 data on treatment for colon infections
12:27pm, Monday, 10'th Aug 2020
Shares of Seres Therapeutics Inc. rocketed nearly fourfold (up 270%) on heavy volume in premarket trading Monday, after the microbiome therapeutics company reported upbeat results of a Phase 3 trial
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
01:05pm, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus treatment/vaccine news flow
Gilead: Perhaps A Value Trap No Longer
11:20am, Sunday, 02'nd Aug 2020
GILD sank back into its familiar pattern of disappointing the Street, selling off below $70 again after reporting Q2 results.
Biotech Bonanza - Second Half Outlook
08:24am, Tuesday, 28'th Jul 2020
Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest cre
Biogen's stock rises after big earnings beat, raised outlook
11:30am, Wednesday, 22'nd Jul 2020
Shares of Biogen Inc. rose 1.4% in premraket trading Wednesday, after the biotechnology company reported second-quarter profit that rose well above expectations, and raised the full-year outlook. Net
Immuron's stock pulls back but still nearly doubles after stock offering
01:00pm, Tuesday, 21'st Jul 2020
Shares of Immuron Ltd. nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered direct offer
Gilead Sciences to pay $300 million for nearly half of Tizona, has option to buy the rest for $1.25 billion
12:43pm, Tuesday, 21'st Jul 2020
Gilead Sciences Inc. announced Tuesday a deal to buy a 49.9% stake in privately held cancer treatment developer Tizona Therapeutics Inc. for $300 million. Gilead also received an option to buy the re
Healthcare Dashboard For July
12:35pm, Tuesday, 21'st Jul 2020
A dashboard with metrics of value, quality and momentum by industries. Value and quality scores relative to historical averages.
ITeos Therapeutics sets IPO terms, to value the company at up to $571.5 million
01:33pm, Monday, 20'th Jul 2020
ITeos Therapeutics Inc. disclosed Monday that it set terms of its initial public offering, in which the biopharmaceutical company focused on cancer treatments could raise up to $160.2 million and be
Nurix Therapeutics sets IPO terms, to be valued at up to $627 million
11:12am, Monday, 20'th Jul 2020
Nurix Therapeutics Inc. disclosed Monday the terms for its initial public offering, in which the San Francisco-based biopharmaceutical company focused on cancer treatments could raise up to $158.4 mi
How COVID Panic Can Be Leading To A New 'Goldilocks' Scenario
02:37am, Monday, 20'th Jul 2020
COVID may be peaking in the US this summer, and if it is not, its share of mind amongst investors may have peaked.
Pandion Therapeutics' upsized IPO priced at the top of the expected range
12:46pm, Friday, 17'th Jul 2020
Pandion Therapeutics Inc. raised more than expected in its initial public offering, which was upsized to 7.5 million shares and priced at $18. The biotechnology company was previously planning to sel
Biotech ETF (IBB) Hits a New 52-Week High
01:45pm, Tuesday, 14'th Jul 2020
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
